By contrast, these findings indicate that the absence of the IGF2BP3-Myc positive feedback loop in this cell type, and other possible differences in post-transcriptional regulatory programs, may contribute to the differential response of this aggressive bone tumor to translation inhibitors. The gene discussed is IGF2BP3; the disease is bone neoplasm.